Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FIASP PENFILL vs FIASP FLEXTOUCH
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis and enhances protein synthesis.
Insulin analog that binds to insulin receptors, lowering blood glucose by facilitating cellular uptake of glucose and inhibiting hepatic glucose production.
Improvement of glycemic control in adults and children with diabetes mellitus,Treatment of diabetes mellitus
Improvement of glycemic control in adults with diabetes mellitus,Treatment of diabetes mellitus in pediatric patients
Subcutaneous injection. Individualized based on blood glucose levels. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into multiple doses, with 50-70% as mealtime insulin and remainder as basal. For type 2 diabetes: 4-6 units with largest meal, titrated up by 2 units every 3-4 days based on glucose monitoring.
Subcutaneous injection at mealtime, 0.2-0.4 units/kg per dose, with total daily dose individualized; typically 50-70% of total daily insulin as bolus, remainder as basal.
0.5–1.0 hours (subcutaneous); terminal half-life corresponds to absorption rate-limited elimination due to rapid dissociation from insulin receptor.
Terminal elimination half-life is approximately 1.3 hours (range 1-1.5 hours) in healthy subjects, corresponding to the rapid clearance of monomeric insulin aspart. This short half-life supports prandial dosing to cover meal-related glucose excursions.
No specific dose adjustment provided in labeling. Use caution; monitor glucose closely and reduce dose as needed due to prolonged insulin action in renal impairment.
No specific dose adjustment; monitor glucose closely due to reduced insulin clearance in severe renal impairment (e GFR <30 m L/min/1.73m²); may require lower doses.
Never share a FIASP Pen Fill between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
Insulin aspart (FIASP PENFILL) does not cross the placenta in significant amounts. No evidence of teratogenicity in human pregnancies. Poorly controlled maternal diabetes carries risks including congenital anomalies, macrosomia, and neonatal hypoglycemia.
Insulin aspart (FIASP) does not cross the placenta in significant amounts; no known teratogenic risk. Poor glycemic control increases congenital malformation risk in first trimester and macrosomia, neonatal hypoglycemia in second/third trimester.
FIASP (faster-acting insulin aspart) has a more rapid onset of action (approx. 2.5 minutes faster than insulin aspart) and earlier peak effect, making it ideal for postprandial glucose control. Administer at start of meal or within 20 minutes after starting meal. Use with caution in patients with gastroparesis due to ultra-rapid absorption. For pump use, compatible with Medtronic and other insulin pumps; ensure no air bubbles in cartridge. Monitor for hypoglycemia, especially in first 4 hours post-injection. Do not mix with other insulins in syringe or vial.
FIASP (insulin aspart) is an ultra-rapid-acting insulin analog with faster onset and shorter duration compared to regular insulin. Onset: ~15 minutes; peak: 1-2 hours; duration: 3-5 hours. Administer at the start of a meal or within 20 minutes after starting a meal. For continuous subcutaneous insulin infusion (CSII), FIASP is approved but may have higher occlusion risk; monitor infusion sites closely. In patients with high insulin requirements, consider splitting bolus doses to reduce late postprandial hyperglycemia. FIASP can be used with all basal insulins including degludec, glargine, and detemir. Avoid in patients with hypoglycemia unawareness or frequent severe hypoglycemia due to its rapid onset. Dose adjustments may be needed in renal or hepatic impairment.
No interactions on record
No interactions on record
FIASP PENFILL and FIASP FLEXTOUCH are distinct pharmacological agents. FIASP PENFILL belongs to the Insulin Analogue class and is primarily used for Improvement of glycemic control in adults and children with diabetes mellitusTreatment of diabetes mellitus. FIASP FLEXTOUCH belongs to the Insulin Analogue class and is primarily used for Improvement of glycemic control in adults with diabetes mellitusTreatment of diabetes mellitus in pediatric patients. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. FIASP PENFILL carries a safety status of Category C, whereas FIASP FLEXTOUCH safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Insulin aspart is metabolized primarily by proteolytic enzymes, likely insulin-degrading enzyme (IDE). It has a half-life of approximately 1.2 hours after subcutaneous administration.
Degraded by insulin protease or insulin-degrading enzymes; metabolism primarily in liver and kidneys.
Primarily renal (glomerular filtration and tubular reabsorption); less than 1% excreted unchanged in bile/feces.
Renal: approximately 60% of administered insulin is excreted via the kidneys, with the remainder undergoing hepatic metabolism and biliary excretion.
<5% bound to plasma proteins (primarily albumin; binding is negligible and not clinically significant).
Approximately 50-60% bound to plasma proteins, primarily albumin and alpha-globulins.
0.2–0.4 L/kg (insulin aspart distributes mainly into extracellular fluid; rapid equilibration).
Volume of distribution (Vd) is approximately 0.3-0.4 L/kg, reflecting distribution primarily into extracellular fluid and tissues.
Subcutaneous: approximately 60–70% (due to local degradation); intravenous: 100%.
Subcutaneous injection: absolute bioavailability is approximately 85-90% (based on euglycemic clamp studies), due to complete absorption from the injection site facilitated by the formulation enhancers.
No specific dose adjustment provided in labeling. Use caution; monitor glucose closely and reduce dose as needed due to decreased gluconeogenesis in hepatic impairment.
No specific dose adjustment; caution in severe hepatic impairment (Child-Pugh class C) due to risk of hypoglycemia; may require dose reduction.
Children aged 1-17 years: Individualized. Typical total daily insulin dose: 0.5-1.0 units/kg/day. For once-daily injections: starting dose 0.25-0.5 units/kg/day. Administer subcutaneously with meals or within 20 minutes after starting a meal.
Children ≥1 year: 0.2-0.5 units/kg per dose administered subcutaneously at mealtime; total daily dose individualized based on glucose monitoring.
Elderly patients: Start with lower doses (e.g., 2-4 units per meal) and titrate slowly to avoid hypoglycemia. Monitor renal function and adjust dose accordingly. Individualize based on glucose targets and concurrent medications.
Initiate at lower doses (e.g., 0.1-0.2 units/kg per meal) due to increased risk of hypoglycemia; titrate slowly based on glucose response.
Never share disposable prefilled pen between patients, even if needle changed, due to risk of transmission of blood-borne pathogens.
No specific food restrictions are required with FIASP. However, patients should coordinate carbohydrate intake with insulin timing. Avoid alcohol consumption which can increase risk of hypoglycemia. Grapefruit does not interact with insulin. High-fat or high-fiber meals may delay absorption of carbohydrates and affect postprandial glucose response, requiring dose adjustment.
No specific food interactions. Must be administered with meals. High-fat meals may delay absorption; monitor postprandial glucose. Avoid alcohol as it may increase risk of hypoglycemia.
Insulin aspart is excreted into breast milk in trace amounts. M/P ratio not established. Unlikely to affect the nursing infant due to oral bioavailability. Use during breastfeeding is considered safe.
Insulin aspart is excreted in breast milk in negligible amounts; M/P ratio not available. Considered compatible with breastfeeding; monitor infant for hypoglycemia if high maternal doses.
Pregnancy can alter insulin pharmacokinetics: increased clearance and reduced sensitivity. Dose adjustments are often required, especially in the second and third trimesters. Frequent monitoring and individualized titration are necessary.
Increased insulin requirements in second and third trimesters due to placental hormones; dose adjustments needed, typically 30-100% increase. Monitor closely to avoid hypoglycemia. Postpartum insulin needs drop dramatically (often to prepregnancy levels).
FIASP works faster than regular insulin aspart; inject at the beginning of a meal or within 20 minutes after starting to eat.,Do not use if the solution is cloudy or contains particles; it should be clear and colorless.,Store unopened vials or cartridges in the refrigerator (36°F to 46°F). Once opened, can be kept at room temperature (up to 86°F) for up to 28 days.,Rotate injection sites within the same body area (abdomen, thigh, arm, or buttock) to avoid lipodystrophy.,Always have a fast-acting source of sugar (glucose tablets, juice) available to treat hypoglycemia.,Do not reuse needles; dispose of sharps in a puncture-proof container.,Consult healthcare provider before adjusting doses, especially during illness, travel, or changes in physical activity.
Inject FIASP in the abdomen, thigh, or upper arm; do not mix with other insulins in the same syringe.,Administer within 20 minutes of starting a meal; if you skip a meal, skip the dose.,Store unopened vials/pens in the refrigerator; once in use, keep at room temperature for up to 28 days.,Rotate injection sites to prevent lipodystrophy.,Monitor blood glucose closely, especially during illness, stress, or changes in diet/exercise.,Recognize symptoms of hypoglycemia (shaking, sweating, confusion) and treat with fast-acting sugar.,Do not share pens; may carry risk of infection.,Check insulin clarity before use; do not use if discolored or contains particles.,Keep extra supply of insulin and supplies for emergency preparedness.,Wear medical identification (e.g., bracelet) for diabetes.